$NMTC

NEUROONE MEDICAL TECHNOLOGIES Corp (NMTC) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 NeuroOne Reports Preliminary Fiscal Q4 Product Revenue Growth of 38.4%; Secures Record $4.5 Million Purchase Order Preliminary Fiscal Q4 2026 Product Revenue of $3.8 Million Preliminary Full-Year Product Revenue Up 15.6% to $10.5 Million, at the Top of Guidance Range

NeuroOne reported preliminary Q4 FY26 revenue of $3.8M, up 38.4% YoY, and FY26 revenue of $10.5M. The company secured a $4.5M purchase order, with $1.0M shipped in September and $3.6M expected in Q1–Q2 FY27. Open purchase orders totaled $5.4M as of September 30.

NeuroOne Medical Technologies Corp (NASDAQ:NMTC) CBO David Wambeke bought 33,333 shares for $66,999 at $2.00-$2.017 each. The stock has since fallen to $1.62, down 68% in six months. Wambeke also acquired options for 35,000 shares. NeuroOne reported a 16% revenue increase to $2.0M in Q3, driven by a 43% surge in OneRF product orders, but faced wider losses.

Wambeke David J. (Chief Business Officer) purchased 33,333 shares of NEUROONE MEDICAL TECHNOLOGIES Corp (NMTC) at $2.01 on 2026-08-27.

NeuroOne Medical Technologies (NMTC) reported that its Chief Administrative Officer, Emily J. Johns, received a grant of 12,500 stock options. The options can purchase common shares at $1.77 per share, expiring on August 27, 2036. 25% vest on August 28, 2027, with the rest vesting in quarterly installments.

NeuroOne Medical Technologies (NMTC) reported that CFO Christopher Volker received options to purchase 35,000 shares at $1.77 each, expiring in 2036. 25% vest in 2027, with the rest vesting quarterly. Volker holds 35,000 option shares post-grant.

NeuroOne Medical (NMTC) CEO David A. Rosa received a grant of 68,000 stock options. The options have an exercise price of $1.77 per share, expire in 2036, and vest over time, with 25% vesting in 2027 and the remainder in quarterly installments.

NeuroOne Medical Technologies (NMTC) reported successful large-animal procedures using its StereoCED platform for drug delivery and electrophysiological monitoring. The company expects to launch human clinical studies this quarter and recognize related revenue in fiscal Q4 2026. The procedures were conducted at the University of Minnesota, demonstrating technical feasibility and validating the integrated surgical and drug delivery workflow.

NeuroOne Medical Technologies (NMTC) announced successful large-animal procedures using its StereoCED platform, enabling simultaneous drug delivery and electrophysiological recording. The company expects its first StereoCED revenue in fiscal Q4 2026, earlier than anticipated, and plans to launch human investigational clinical studies by the end of the quarter. The platform is not yet approved for commercial use.

NeuroOne Medical Technologies reported Q3 2026 revenue of $2.0M, up 16% YoY, with gross margin expanding to 59.9%. Product orders rose 43% YoY to $2.7M. Net loss increased to $2.0M. The company expects $9.2M-$10.5M revenue for fiscal 2026. Cash reserves totaled $2.0M. NeuroOne was added to the Russell Microcap Index. The stock is down 2.30%.